Chester B. Whitley - Concepedia

Author

Chester B. Whitley

Also Known As

C B Whitley, CHESTER B. WHITLEY, Chester Buchan Whitley, Chester B Whitley, Chester B. Whitley, Chester Buchan Whitley, Chester Whitley, Matthias Vorgerd, Whitley, Chester B.

406

Publications

7.7K

Citations

H-Index

162

Concepts

All Affiliations

University of Minnesota University of Minnesota Medical Center Pediatrics and Genetics UCSF Benioff Children's Hospital University of California, San Francisco

About

Chester B. Whitley is an author at University of Minnesota specializing in medicine, pathology, and lysosomal storage disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	56	3.5K
2	Health Sciences	4	4	95
3	Education	3	3	108
4	Natural Sciences	2	2	67
5	Engineering	1	1	38

Chester B. Whitley

112

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
Agalsidase-Beta Therapy for Advanced Fabry Disease Maryam Banikazemi, Jan Bultas, Stephen Waldek, Annals of Internal Medicine	2007	564
Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study Harvey L. Levy, Andrzej Milanowski, Anupam Chakrapani, The Lancet Sapropterin DihydrochlorideRenal FunctionChronic Kidney DiseasePharmacologyPhase Iii	2007	307
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) Paul Harmatz, Chester B. Whitley, Lewis Waber, The Journal of Pediatrics Rare DiseasesEnzyme Replacement TherapyGenetic DisorderPathogenesisPathology	2004	273
Phenylketonuria Scientific Review Conference: State of the science and future research needs Kathryn Camp, Melissa A. Parisi, Phyllis B. Acosta, Molecular Genetics and Metabolism Translational MedicineChronic Kidney DiseaseRenal PathologyPathologyTranslational Research	2014	263
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Molecular Genetics and Metabolism Translational MedicineEnzyme Replacement TherapyPathologyMucopolysaccharidosis ViSafety Outcomes	2008	215
Long‐term outcome of Hurler syndrome following bone marrow transplantation Chester B. Whitley, Kumar G. Belani, Pi‐Nian Chang, American Journal of Medical Genetics	1993	193
Efficacy of Sapropterin Dihydrochloride in Increasing Phenylalanine Tolerance in Children with Phenylketonuria: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Friedrich K. Trefz, Barbara K. Burton, Nicola Longo, The Journal of Pediatrics Sapropterin DihydrochlorideMedicineInherited Metabolic DiseaseClinical NutritionPharmacology	2009	190
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf, The Lancet Neurology Late-onset Pompe DiseaseAutoimmune DiseaseClinical Infectious DiseaseMedicinePhase 3	2021	169
Biodistribution and Toxicity Studies of VSVG-Pseudotyped Lentiviral Vector after Intravenous Administration in Mice with the Observation of in Vivo Transduction of Bone Marrow Dao Pan, Roland Günther, Wei‐Ming Duan, Molecular Therapy	2002	139
Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing Kanut Laoharawee, Russell C. DeKelver, Kelly M. Podetz-Pedersen, Molecular Therapy	2018	119

Page 1